Command Palette

Search for a command to run...

Preprint WatchModerateJuly 6th, 2026

Peptide allosteric inhibitor of TNFR1 signaling attenuates inflammation and rheumatoid arthritis pathology in human TNF transgenic mice

Riyed, T. H.; Kalary, K.; Zeng, J.; Lo, C. H.

A peptide allosteric inhibitor (FKC) that selectively blocks TNFR1 signaling, rather than globally neutralizing TNF, improved clinical scores and reduced inflammation in a human TNF transgenic mouse model of rheumatoid arthritis.

Moderate contradiction

1 prior failure

Two documented clinical failures match this mechanism, or a single Phase 3 failure is on record.

This preprint pursues receptor-selective inhibition of TNFR1 to avoid the liabilities of global TNF blockade, and reports reduced inflammation and improved function in a human TNF transgenic rheumatoid arthritis model. The Claidex record for TNF holds one indexed failure, INB03 (pegipanermin), a dominant-negative agent that neutralized soluble TNF in COVID-19 acute respiratory distress and did not meet its efficacy endpoint (inb03-soluble-tnf-covid19-ards-futility). The preprint does not contradict that result. It reframes the axis, because the indexed failure neutralized the ligand in an acute respiratory setting while the preprint blocks one receptor conformer in a chronic autoimmune setting where TNF biology is far better validated. The mechanistic distinction between ligand neutralization and TNFR1-selective allosteric block is the variable that separates the two, and it argues for indication and node selection rather than abandonment of the pathway.

Abstract excerpt

Inhibition of tumor necrosis factor receptor 1 (TNFR1) represents a major therapeutic strategy for chronic autoimmune and inflammatory diseases such as rheumatoid arthritis (RA). As current anti-TNF therapies can cause adverse side effects due to global blockade of the ligand, receptor-specific inhibition of TNFR1 signaling has emerged as a highly sought-after strategy. A novel peptide-based allosteric inhibitor, FKC, targets the TNFR1 conformationally active region to alter receptor conformational states and disable the receptor-ligand signaling complex. In a human TNF transgenic mouse model of RA, FKC treatment improved clinical RA scores, enhanced grip strength, increased walking distance, and inhibited TNF/TNFR1-mediated inflammation.

Matching Claidex post-mortems

1 of 1 indexed

This is an automated contradiction flag, not an editorial judgment on the preprint's quality. Flags identify where the preclinical literature and the clinical failure record diverge.